SCHEDULE 13G/A: Ridgeback Capital Updates Passive Stake in Pyxis Oncology to 0.6%

Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% in Pyxis Oncology, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 1 to Schedule 13G for Pyxis Oncology, Inc. (Issuer CUSIP: 747324101).
• The reporting persons are Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC, all Delaware entities.
• As of December 31, 2024, the aggregate amount beneficially owned by each reporting person is 359,231 shares of Pyxis Oncology, Inc. Common Stock.
• This beneficial ownership represents 0.6% of the class of securities outstanding.
• The reporting persons hold shared voting power and shared dispositive power over all 359,231 shares.
• Ridgeback Capital Investments LLC is the general partner of Ridgeback Capital Investments L.P., and Ridgeback Capital Management LLC maintains investment and voting power with respect to securities held or controlled by Ridgeback Capital Investments LLC.
• Wayne Holman controls Ridgeback Capital Management LLC.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing passive beneficial ownership, which is neutral in sentiment as it provides factual information without indicating positive or negative operational or financial performance.

Positives

• The disclosure of a passive institutional holder like Ridgeback Capital provides transparency to the market regarding the company's shareholder base.

Future Outlook

NA

Industry Context

This document is a routine regulatory filing (Schedule 13G) common across all publicly traded industries, indicating a passive ownership stake by an investment entity. It does not provide specific industry trends or competitive analysis for the biotechnology sector in which Pyxis Oncology operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the presence of a passive institutional investor.

Key Dates

Keywords

Pyxis Oncology, Ridgeback Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing